Celebrating Innovation: Georgia Bio Summit 2024 Company Showcase Winners

The Georgia Bio Summit 2024 was a remarkable gathering of life sciences leaders, innovators, and changemakers. This year’s Company Showcase featured 10 groundbreaking companies, all showcasing the cutting-edge innovation happening right here in Georgia and beyond. The level of competition was truly exceptional, and we are excited to announce the Top 3 Winners of the 2024 Showcase Summit:



1st Place: OrthoPreserve

OrthoPreserve impressed the judges with its innovative solutions in regenerative medicine and tissue preservation, paving the way for advancements in orthopedic care. Their work is not only transforming how we approach patient recovery but also demonstrating the impact of cutting-edge research in improving outcomes.


2nd Place: JellyCo USA

JellyCo USA stood out with its groundbreaking advancements in marine biomaterials. Their work is leading the charge in sustainable and scalable solutions for various applications, creating a meaningful impact on the future of life sciences.


3rd Place: NeurOp

NeurOp continues to push boundaries in neurological drug development, addressing unmet needs for patients with brain and nervous system disorders. Their innovation reflects a deep commitment to improving lives through science and discovery.


Honoring All Participants

While we celebrate our winners, we want to shine a spotlight on the other incredible companies that were part of this year’s showcase. These organizations exemplify the innovative spirit driving life sciences forward:

  • Atomistic Insights
  • Autofrax
  • Lena Biosciences
  • ARNAV Biotech
  • Intelligent Dots
  • Annoviant
  • OncoSpherix


Your dedication to advancing health and science inspires us all. Each of you contributes to making Georgia a hub for life sciences innovation, and we are honored to have you as part of our community.


A Bright Future for Georgia Life Sciences

This year’s Company Showcase proved that the future of life sciences in Georgia is brighter than ever. The level of talent, innovation, and collaboration on display underscores the importance of fostering a thriving ecosystem for startups and established companies alike.

As we look ahead, Georgia Bio remains committed to supporting these companies through programs, partnerships, and initiatives that drive growth and opportunity in the life sciences sector. Together, we’re not just building businesses – we’re improving lives and creating a healthier tomorrow.


Congratulations again to all participants and especially to our winners, OrthoPreserve, JellyCo USA, and NeurOp. We can’t wait to see the incredible advancements you’ll achieve in the coming years.


#GeorgiaBioSummit #LifeSciences #Innovation #Entrepreneurship #CompanyShowcase2024

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: